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Summary 
Background Post-mastectomy radiotherapy (PMRT) in patients with 4+ axillary nodes reduces breast 
cancer mortality, but its role in patients with 1-3 involved nodes is controversial. 
Methods BIG2-04-MRC-EORTC SUPREMO is an international parallel randomised controlled trial. 
Eligible women (over 18 years, with  ?ŝŶƚĞƌŵĞĚŝĂƚĞƌŝƐŬ ?ďƌĞĂƐƚĐĂŶĐĞƌ, pT1-2N1, pT3N0 and pT2N0 if 
grade III and/or lympho-vascular invasion, post-mastectomy and axillary surgery) were randomly 
assigned to receive chest-wall radiotherapy (50 Gy 25 fractions or radiobiolgically equivalent 45 Gy 
20 fractions or 40 Gy 15 fractions) or not (1:1 ratio).  Randomisation was in permuted blocks with 
varying block length, stratified by centre, without masking of patients or investigators.  The primary 
endpoint is 10-year overall survival. Here, we present the 2-year quality of life (QOL) results (pre-
specified secondary endpoint). The QOL substudy, open to all UK patients, consists of questionnaires 
(EORTC QLQ-C30 and BR23, Body Image Scale, Hospital Anxiety and Depression Scale (HADS) and EQ-
5D-3L) completed pre-randomisation, 1, 2, 5 and 10 years.  Data were analysed on an intention-to-
treat basis, using repeated mixed-effects methods. The trial is registered with International Standard 
Randomised Controlled Trials (ISRCTN61145589). 
Findings  
Between August 4,2006-April 29, 2013, 1688 patients enrolled internationally, 989/1258 (79%) of 
the UK patients consented to QOL substudy. Patients receiving PMRT reported worse chest-wall 
symptoms (p=0·016) but the difference was small. Symptoms improved from year 1 to 2. 
Chemotherapy was associated with less improvement.  No group differences were observed for arm 
symptoms, body image, fatigue, pain, overall QOL, physical functioning or HADS scores.  
Interpretation PMRT led to more local symptoms up to 2 years post-randomisation, but the 
difference was small. This data will inform shared decision-making whilst survival results (main trial 
endpoint) become available.   
 
Funding Medical Research Council, European Organisation for Research and Treatment of Cancer, 
Cancer Australia, Dutch Cancer Society, Trustees of Hong Kong Shanghai Banking Corporation. 
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Research in Context 
Evidence before this study 
Adjuvant chest-wall irradiation after mastectomy remains a core effective element in the loco-
regional management of early breast cancer reducing loco-regional recurrence and breast cancer 
mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients with 4 or 
more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes 
is controversial and practices vary. The Oxford overview in 2014 shows an advantage in overall 
survival from PMRT in patients with 1-3 positive nodes. However, the generalisability to 
contemporary practice of historical trials with different standards of surgery, radiotherapy and 
systemic therapy remains uncertain.  Benefits in survival needs to be balanced against risk of loco-
regional and cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic 
anthracyclines and trastuzumab. The recent American Society of Clinical Oncology guidelines on the 
use of PMRT emphasizes the importance of evaluating the risk-benefit ratio, but the overview data is 
derived from patients treated several decades previously and only a limited number of small studies 
looked at patient-reported outcomes, such as symptoms and quality of life. 
Added value of this study 
Our study uniquely investigated the impact of adjuvant PMRT on quality of life in a randomised trial 
ŝŶĐůƵĚŝŶŐĂůĂƌŐĞ ?ǁĞůůĐŚĂƌĂĐƚĞƌŝƐĞĚƉŽƉƵůĂƚŝŽŶŽĨh<ƉĂƚŝĞŶƚƐǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂte-ƌŝƐŬ ?ďƌĞĂƐƚĐĂŶĐĞƌ 
post-mastectomy. At 2 years PMRT was associated with worse self-reported local symptoms (pain, 
ƐǁĞůůŝŶŐ ?ƐŬŝŶƉƌŽďůĞŵƐŝŶƚŚĞ “ĂƌĞĂŽĨƚŚĞĂĨĨĞĐƚĞĚďƌĞĂƐƚ ? ?ŝŶĐŽŵƉĂƌŝƐŽŶǁŝƚŚŶŽƌĂĚŝŽƚŚĞƌĂƉǇ ?ďƵƚ
the difference is small, unlikely to be of clinical significance and the symptoms improved over time. 
There were no differences in arm symptoms, body image, fatigue, pain, overall QOL, physical 
functioning anxiety or depression. 
Implications of all the available evidence 
The impact on PMRT on 10-year survival, the primary endpoint of the main SUPREMO trial, will not 
be known before 2023. In the meantime, both options of administering or omitting PMRT are 
legitimate for patients in the intermediate risk category (1-3 positive lymph nodes). Our data will 
inform shared decision-making (as recommended in the recent North American guidelines on PMRT) 
and put patients in a better position to make an informed value judgment on what they consider 
relevant for their situation given the data on the patient-reported symptoms and QOL domains 
presented in this report. Both physicians and patients may be helped when weighing up the 
individual estimates of possible benefits of radiotherapy against the impact of PMRT on toxicity and 
quality of life. 
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Introduction 
Current multimodality treatment for breast cancer has improved survival rates. 1 Avoiding 
overtreatment and balancing the treatment burden against benefit has become an important 
research field. Examples of trials investigating selective omission of radiotherapy or chemotherapy 
have recently been reported. 2,3  While the impact of mastectomy and chemotherapy on quality of 
life has been well documented the additional effect of adjuvant radiotherapy following mastectomy 
is unclear. Chest wall pain, fatigue, anxiety about recurrence and depressive symptoms can all hold 
back recovery and return to normal activities of daily living. 4 
Adjuvant chest wall irradiation after mastectomy remains a core and highly effective element in the 
loco-regional management of early breast cancer reducing loco-regional recurrence and breast cancer 
mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients with 4 or 
more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes 
is controversial and practice and guidelines vary.5 The Oxford overview in 2014 shows an advantage 
in overall survival from PMRT which included at least the chest wall in the target volume in patients 
with both 1-3 and 4 or more positive nodes.6 However, the generalisability of historical trials with 
different standards of surgery, radiotherapy and systemic therapy remains uncertain, especially as 
contemporary survival rates are much higher than in the studies included in the overview.  Potential 
benefits in survival needs to be balanced against risk of loco-regional and cardio-pulmonary toxicity, 
particularly in conjunction with potentially cardiotoxic anthracyclines and trastuzumab. A recent 
update by the American Society of Clinical Oncology on the use of post-mastectomy radiotherapy 
emphasises the importance of evaluating the risk-benefit ratio, particularly in patients with a low risk 
of local failure.7 The benefit of PMRT relies on estimates of recurrence risk, modulated by biological 
tumour characteristics, weighed against the negative impact of PMRT on the risks of late toxicity (e.g. 
cardiac toxicity from radiotherapy may be increased by the combination with systemic therapy).8 The 
data currently available on these modulating effects is derived from patients treated several decades 
previously. 
Selective use of post-mastectomy radiotherapy is being evaluated in the BIG 2.04 MRC EORTC 
SUPREMO trial, which assesses the effects of adjuvant chest wall radiotherapy without axillary 
irradiation in patiĞŶƚƐǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂƚĞƌŝƐŬ ?early breast cancer who have undergone mastectomy 
and adequate systemic therapy following contemporary guidelines for all treatment modalities. This 
is the largest randomised trial to date to assess the role of PMRT in this subset of patients. The 
endpoints have been previously described. 9 In brief, the primary endpoint of the trial is overall 
survival at 10 years. Secondary end points include various breast cancer recurrence endpoints, 
toxicity, acute and late morbidity (cardiac morbidity and mortality) and quality of life. Sub-studies 
include the TRANS-SUPREMO seeking molecular markers of radiosensitivity, a cardiac substudy, and 
for UK patients only Quality of Life (QOL) assessment and Health Economics evaluation. These sub-
studies will provide an important high-quality evidence base on the balance of potential benefits and 
treatment burden, to support patients and health care professionals during shared decision-making. 
The long-term impact of breast cancer and its treatment on everyday life has been identified as a 
critical knowledge gap and a key priority for breast cancer research 10. For radiotherapy, there is a 
limited information on treatment impact.  A small number of trials have investigated self-reported 
breast, arm, and shoulder symptoms, functional outcomes and quality of life after radiotherapy, 
predominantly in breast conserving therapy11-13. Patients usually report transient and short-term 
effects of radiotherapy, with relatively limited effect on overall quality of life 14,15 .  
No comprehensive QOL data exists in patients having PMRT and only a few studies have compared 
patient-reported outcomes following breast-conserving surgery versus mastectomy with and 
without reconstruction. Recent introduction of oncoplastic surgical techniques is expected to have 
an impact on post-treatment morbidity and patient satisfaction with body image16,17. There is a 
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dearth of level 1 evidence assessing the impact of adjuvant post-mastectomy radiotherapy on QOL 
of patients who have undergone reconstruction.  
The SUPREMO QOL substudy aimed to examine the effects of PMRT on several primary QOL 
outcomes (global QOL, fatigue, physical function, chest wall, shoulder and arm symptoms, body 
image, anxiety and depression) at 1, 2, 5, and 10 years post treatment. Here we report the 2-year 
results. To our knowledge, this is the first study looking at the impact of adjuvant radiotherapy on 
QOL in a large randomised trial confined to patients treated by mastectomy for early breast cancer 
(including patients undergoing breast reconstruction). 
Methods 
Study design and Participants 
SUPREMO was an open label parallel randomized trial. Patients provided written informed consent 
before enrolment.  The full eligibility, exclusion criteria and trial procedures are described in the trial 
protocol provided in the supplementary web material and online (http://www.supremo-
trial.com/SUPREMO%20protocol%20version29.pdf). Briefly, eligible patients were women aged 18 
years or older if they had undergone mastectomy for unilateral breast cancer, and an axillary staging 
procedure with axillary lymph node dissection, iĨŶŽĚĞƉŽƐŝƚŝǀĞ ?WĂƚŝĞŶƚƐǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂƚĞƌŝƐŬ ? 
breast cancer were eligible, defined as pT1-2N1, pT3N0 and pT2N0, if also grade III and/or with 
lympho-vascular invasion on histology. Patients needed to be fit for surgery, radiotherapy or 
adjuvant systemic therapy. Exclusion criteria included previous or concurrent malignancy (except 
non-melanomatous skin cancer and carcinoma in situ of the cervix), ductal carcinoma in situ, 
bilateral breast cancer, pregnancy at the time of radiotherapy treatment and male gender. 
All patients had to receive adequate systemic therapy following contemporary guidelines depending 
on patient and tumour characteristics. If this included chemotherapy, treatment regimes containing 
at least 4 cycles of anthracyclines were recommended. Adjuvant trastuzumab was given according to 
local practice. In 2011 the eligibility criteria were widened, following a protocol amendment 
approved by the Ethics Committee, to include neo-adjuvant chemotherapy.   
For patients randomized to chest wall radiotherapy, radiation was given after the chemotherapy 
(when given). Radiotherapy treatment consisted of chest wall radiation to a total dose of 50 Gy in 25 
daily fractions of 2 Gy over 5 weeks. Other permitted radiobiologically equivalent schedules included 
45 Gy in 20 fractions over 4 weeks, and 40 Gy in 15 fractions over 3 weeks. Guidelines on treatment 
planning and set up were given, and there was a radiotherapy quality assurance programme in the 
trial. The use of bolus was permitted and had to be pre-specified per centre. Axillary irradiation was 
not permitted, but medial peri-clavicular and/or internal mammary chain irradiation was permitted 
according to local policy of the centres. Boost radiation was not permitted.  Surgery, systemic 
therapy and pathology were also subject to pre-specified quality assurance. Additional recorded 
data included cardiovascular risk factors, radiotherapy cardiac and lung exposure parameters, 
systemic therapy (type, doses, and dates) and any reconstructive surgery (type, immediate or 
delayed). Patients with gross protocol violations (e.g. margins involved or less than 1mm for invasive 
cancer or DCIS) will be removed before the final analysis of the main trial.  A mammogram of the 
opposite breast, if appropriate, was recommended at least in alternate years for 10 years from the 
date of mastectomy. The primary endpoint of the trial, overall survival, is not centrally reviewed. 
Serious adverse events were to be reported if they occurred during radiotherapy or within 30 days of 
the last radiotherapy session (fraction) whether or not they were related to the randomised 
treatment. Any toxicity assessed as a grade 4 or 5 acute or late morbidity score had to be reported 
on a SAE/SUSAR form for the entire follow up period of the trial. Adverse events were reviewed by 
the Data Monitoring and Ethical Committee meeting every 6 months (or as often as they considered 
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appropriate). Monitoring (source data verification) is carried out by the Cancer Clinical Trials Team in 
Edinburgh on 10% of the patient data of the main trial with site visits allowed in the UK. Higher 
levels of monitoring will be performed, if requested by the Data Monitoring Committee, or if 
particular safety issues are identified by the investigators, the trial management group of the trial 
steering committee. 
The study was approved by the Multi-Centre Research Ethics Committee, Edinburgh (MREC 
05/50501/106) and local research and development offices. Patients provided written informed 
consent before enrolment and had additional options to consent to the sub-studies, including QOL 
substudy. 
Randomisation and masking 
Consenting patients were randomized post-operatively to either chest-wall radiotherapy or no 
chest-wall radiotherapy (1:1 ratio). Patients were randomised by permuted blocks with the block 
length being varied randomly to minimise the effect of entry bias.  Stratification was by treatment 
centre due to possible between centre differences in the manner in which radiotherapy is given.  
There was no masking by patients or investigators. Randomisation was performed via a telephone 
call to The Information and Statistical Division (ISD) at National Services Scotland. 
Procedures for QOL substudy 
All patients eligible for SUPREMO from UK centres were invited to participate in the QOL study. 
Patients who provided informed consent completed a questionnaire booklet in the clinic before 
randomisation. Completed bŽŽŬůĞƚƐǁĞƌĞƐĞŶƚƚŽƚŚĞƚƌŝĂů ?ƐŽĨĨŝĐĞĂŶĚƐubsequent questionnaires 
were posted to patients at 12 and 24 months ďǇƚŚĞƚƌŝĂů ?ƐŽĨĨŝĐĞ. If the baseline questionnaire was 
not returned to the trial ?s office further questionnaires could not be sent, as patients ? names and 
addresses were not available to the trial co-ordinator. Reminders were sent to the hospitals where 
baseline questionnaires were overdue. No reminders were sent to patients at 12 and 24 months. 
QOL was assessed using several well-validated questionnaires. 
EORTC QLQ-C30 (version 3·0) and the breast module QLQ-BR23 (version 1·0). The QLQ-C30  
consists of 30 questions addressing 5 functional scales (cognitive, emotional, physical, social, and 
role), 9 symptom scales (appetite loss, constipation, diarrhoea, dyspnoea, fatigue, financial 
difficulties, insomnia, nausea and vomiting, and pain), and one Global Health Status/QOL scale18. The 
EORTC QLQ-BR23  focuses on breast cancer specific issues and includes 23 questions addressing 4 
functional: body image, future perspective, sexual enjoyment, and sexual functioning and 4 
symptom scales: arm symptoms (swelling in arm or hand, arm or shoulder pain, and difficulty raising 
the arm), breast/chest wall symptoms (pain, swelling, oversensitivity, and skin problems in the area 
of the affected breast), systemic therapy side-effects, and upset by hair loss19. All scores for the 
EORTC QLQ-C30 and EORTC QLQ-BR23 were transformed to a scale from 0 to 100. Higher scores on 
the functional scales and Global QOL represent a superior level of functioning and better QOL, 
whereas higher scores in the symptom scales or items represent worse symptoms. 
The Body Image Scale (BIS) is a 10-item scale designed specifically for use with cancer patients to 
assess aspects of attractiveness, sexual attractiveness and feelings or satisfaction with appearance.  
Scores were graded 0-3 and summed to produce a single score, where a higher score indicated more 
problems (score range from 0 to 30)20. 
Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument with two sub-scales for 
anxiety and depression21. Scores range from 0 to 21 on each scale, with higher scores indicating 
more distress. Scores above 11 suggest probable cases of anxiety or depressive illness, and scores 
between 8 and 10 indicate borderline cases. A combined score of 19 or above is considered 
indicative of psychological distress. 
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EQ-5D-3L questionnaire measures health status across five domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Respondents specify whether they have no 
problems, some problems or severe problems within each domain, on the day of response. These 
EQ-5D-3L health states descriptions are converted into a single summary index (range from 0 to 1) 
by attaching a value to each of the levels in each dimension. As is standard practice, these values 
were obtained from a large UK population study using a choice-based method of valuation. 22 The 
resulting summary score, or utility value, can then be used directly in the cost-utility analysis.  
Outcomes 
The primary endpoint of SUPREMO trial is 10-year overall survival. Quality of life is a secondary 
endpoint alongside chest-wall recurrence, regional recurrence, disease free survival, acute and late 
morbidity and cost-effectiveness. In the QOL substudy we pre-specified as primary outcomes global 
QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, 
anxiety and depression. Secondary outcomes are role, social, sexual functioning, pain and 
nausea/vomiting. 
Statistical analysis 
Sample size for the SUPREMO QOL study was considered as a problem of estimation rather than a 
significance testing. With 200 evaluable patients per group the proportion of patients exhibiting a 
particular side-effect or specified degree of morbidity in a QOL domain could be estimated with a 
standard error of 3·5% or less. The corresponding difference between the groups could be estimated 
with a standard error of 5% or less.  However, as there is usually a significant attrition over time, in 
order to have sufficient numbers by 10 years a target of 800 patients was set. The total sample size 
of SUPREMO was reduced during the course of the trial, following a protocol amendment approved 
by the ethics committee, from 3500 to 1600 but this did not affect the QOL substudy sample. 
When calculating QOL questionnaire or sub-scale scores, we followed official questionnaire 
guidelines on handling missing individual items. In general, if more than 50% of the items were 
missing, sub-scale scores ware not calculated (missing); if less than 50% of items were missing, those 
were replaced by the mean of the answered items and a score was calculated. Where no guidance 
existed, that score was recorded as missing. 
In order to maintain the Normality of the residuals, the difference from baseline to each subsequent 
questionnaire was calculated for each scale. Repeated analysis of covariance was conducted using 
PROC MIXED, to allow for observations that are missing at random. Time and treatment allocation 
interactions were tested for each scale but are to be reported only where statistically significant. 
Baseline scores were included in each model as a covariate. As the QOL study was not originally 
powered for hypothesis testing, p-values are only included for illustration. However, the treatment 
with radiotherapy was our primary outcome, and any results that have a p-ǀĂůƵĞŽĨч ? ? ? ?ǁŝƚŚƚŚŝƐ
variable will be discussed. Due to the large number of models, clinical variables will only be 
discussed if they exceed the more conservative threshold value of 0.01. 
The principal analysis modelled the change in score in the pre-specified QOL outcomes (global QOL, 
fatigue, physical function, chest wall, shoulder and arm symptoms, body image, anxiety and 
depression) by time (visit 1 at 12 months or 2 at 24 months) of follow up, age group (<45, 45-54, 55-
 ? ? ?ш ? ? ?, baseline score and treatment (± radiotherapy).  
As almost all patients received some form of systemic therapy and some underwent breast 
reconstructive surgery, secondary exploratory analyses were performed to evaluate whether these 
treatments influenced the QOL outcome measures. The secondary analysis included clinical 
covariates also considered to have an impact on QOL (extent of axillary surgery, early breast 
reconstruction, adjuvant chemotherapy, adjuvant hormonal therapy and trastuzumab). This was 
 8 
performed by creating a basic model of age group, time and baseline score, then adding the clinical 
variables in turn to create a model of best fit. This process was then repeated until no variables 
added significantly to the model. The radiotherapy variable was then added to the best fit model. 
Only patients with complete data for all clinical variables were included in this modelling. 
All analyses were on an intention to treat basis. No additional sensitivity analyses or interim analyses 
were planned for this stage of the trial. The analysis was generated using version 9·4 of the SAS 
System for Windows (www.sas.com Copyright © 2012 SAS Institute Inc. SAS and all other SAS 
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., 
Cary, NC, USA.)  
This study is registered as an International Standard Randomised Controlled Trial, number 
ISRCTN61145589. 
Role of Funding Source  
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author and the joint senior authors had 
full access to all data in the study and had final responsibility for the decision to submit for 
publication. 
 
Results 
Between August 4, 2006 and April 29, 2013 the trial recruited 1688 patients internationally. All 
patients eligible for SUPREMO from 111 UK centres were invited to participate in the QOL substudy 
(n=1258). This approach was adopted in order to avoid any bias in selecting centres or patients. The 
consent rate between centres varied (see Table consent rates in the web appendix, page 1). The 
majority of the centres (73 centres) had consent rates of 80% or above. Ten centres did not include 
any of their 66 patients in the QOL study. A total of 989 (79%) UK patients consented to participate, 
of them 95·7% (947/989) patients (returned the baseline questionnaires (476/502 94·8% in the 
control and 471/487 96·7% in the radiotherapy arm). The statistical analysis is based on 947 patients 
who returned the baseline QOL questionnaires (Figure 1). Due to the practical arrangements for the 
QOL data collection, questionnaires for years 1 and 2 could be sent only to patients who returned 
the baseline questionnaire. We have not formally recorded reasons for declining participation as 
according to the Ethics Committee approved patient information sheet, patients were not obliged to 
provide such reasons. The patients from UK who declined participation or did not return the baseline 
questionnaires were older (n=311 mean age 57.7 years, SD 11.9) than those who consented and 
returned the baseline questionnaire (n=947 mean age 56.1 years, SD=11.0; p=0.02). Comparing the 
age of QOL study participants with the rest of the main trial (UK patients not participating in QOL 
study and all patients from other countries) did not show an age difference (n=741 mean age 55.6 
years, SD 11.6, p=0.34).  In order to check further for potential bias in patient selection for the QOL 
substudy, we compared the clinical characteristics of the patients completing the QOL substudy with 
those of the patients in the main trial in Table 1. 
Good patient compliance was achieved with the completion of QOL measures: at year 1 388/466 
83·3% in the control group and 388/467 83·1% in the radiotherapy group; at year 2 (350/463 75·6% 
and 367/457 80·3% respectively. A slightly better compliance was observed in the radiotherapy arm 
at baseline and year 2 (Figure 1).  
Median follow-up for the patients who returned the baseline questionnaires was 748 days  
(interquartile range 417-763) for the control group and 749 days (interquartile range 725-762) for 
radiotherapy group.  
 
Patient characteristics 
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WĂƚŝĞŶƚƐ ? demographic, clinico-pathological characteristics and treatment details are shown in Table 
1. Two-thirds of patients had T2 tumours, slightly over half were Grade 3, over 78% were ductal 
carcinomas, approximately 20% were oestrogen/progesterone receptor negative, and 30% Her2 
positive. Only a small proportion of just over 10% had immediate reconstruction, and 10% late 
reconstruction (by 2 years). A further review of the type of breast reconstruction suggested more 
frequent autologous reconstructions in the radiotherapy group, whereas there were more 
reconstructions with an implant/expander in the control group (see Web appendix, page 2).  This 
trend was observed for both the immediate and the late reconstructions.  Over 80% of participants 
had adjuvant chemotherapy, 20% trastuzumab and over 70% endocrine therapy. No differences are 
observed between the QOL participants and the full trial.  
The majority of patients in the radiotherapy group of the QOL study received 40 Gy in 15 fractions 
(69%, 327/478), with the remaining patients equally divided between 50 Gy in 25 fractions (11%, 
52/478), 45 Gy in 20 fractions (10%, 48/478) and other/unknown (10%, 51/478). In the main trial, a 
smaller proportion of 52% (445/853) received 40 Gy in 15 fractions, a larger proportion of 27% 
(227/853) had 50 Gy in 25 fractions, 7% (57/853) had 45 Gy in 20 fractions and 15% (124/853) - 
other/unknown. The dose for all EORTC centres was 50 Gy in 25 fractions. 
Baseline and follow-up QOL scores are shown in Table 2. Baseline scores were reported following 
surgery and prior to randomisation. Of note, patients reported relative impairment in global QOL 
with a mean score of 60 (100 is excellent), a high level of fatigue (mean of 40, where 100 is greatest 
degree of fatigue), insomnia (mean of 36-37; 100 is worse) and a degree of arm symptoms, chest 
wall symptoms and pain (in the range of 17 to 24; 100 is worst symptom).  
Pre-specified primary QOL outcomes 
Table 3 presents the results from mixed-effects models analysis of pre-specified primary QOL 
outcomes and pain (a pre-specified secondary QOL outcome).  The tested clinical variables are 
included in Table 3 where they were found to have a significant effect (p<0.01) on either the 
radiotherapy treatment or on changes over time. Such effects were found for adjuvant 
chemotherapy and immediate breast reconstruction but not for extent of axillary surgery, adjuvant 
endocrine therapy or trastuzumab. 
Chest wall symptoms were worse in the group receiving radiotherapy (estimate of effect 2·17; 95% 
Confidence Interval (CI) 0·40, 3·94; p=0·016). There was an improvement between years 1 and 2 
(visit effect -1.34; 95% CI -2·36, -0·31; p=0·010), but the improvement was smaller in the 
radiotherapy group (Figure 2a). Of the clinical factors the use of chemotherapy was associated with 
less improvement in chest wall symptoms but there was no interaction with radiotherapy, 
suggesting an additive effect of chemotherapy (Figure 2a).  There was a borderline age effect, with 
patients <45 years having worse chest-wall symptoms than those ш ? ? years (estimate of effect 4·49; 
95% CI 0·59, 8·39; p=0·022). 
Arm problems did not differ significantly according to radiotherapy treatment (Figure 2b), they 
improved in both group between years 1 and 2, with a greater improvement in older patients (data 
not shown). When clinical variables were included the effect of age was no longer apparent. 
However, chemotherapy had an effect with patients receiving chemotherapy showing less 
improvement of arm symptoms over time, suggesting that chemotherapy and age were 
confounders. Significantly more patients who received chemotherapy were in the younger age group 
(97% of patients <45 years, 97% in 45-54 years, 85% in 55-69 years, 37% in ш ? ? years groups, P < 
0·0001). Contrary to the clinical expectations, the extent of axillary surgery (comparison of 3 types: 
1) sentinel node biopsy or node sampling; 2) sentinel node biopsy plus axillary node clearance; 3) 
axillary node clearance) did not have an effect on arm/shoulder symptoms scores (see Web 
appendix, page 3). Furthermore, the extent of axillary surgery did not have an impact on any of the 
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pre-specified QOL variables, except a trend for higher HADS-Anxiety in patients with sentinel node 
biopsy plus axillary node clearance. 
Despite the observed differences in chest-wall symptoms patients reported relatively few body 
image problems with improvement between years 1 and 2. Some age effect was observed with 
patients <45 years old reporting more concerns about their body image in comparison with patients 
ш ? ? years old (estimate of effect 1·96; 95% CI 0·53, 3·39; p=0·0074). 
The overall QOL of patients was not affected by radiotherapy treatment. Furthermore, improvement 
in overall quality of life was observed between baseline and year 1 with further but smaller 
improvement by year 2 (Figure 2c).  
Physical function was not affected by treatment and no change was observed over time (Figure 2d). 
As expected there was an age affect with the younger age group reporting better overall physical 
functioning (Table 3). 
Patients reported high baseline level of fatigue, likely due to the preceding surgery. Significant 
improvement between year 1 and 2 was observed. Immediate reconstruction had a borderline 
impact on the change scores at year 1 (estimate of effect 5·32; 95% CI 0·94, 9·69; p=0·017), possibly 
related to slower recovery from the operation (Figure 2e), but without detectable differences in 
overall QOL or body image. 
No group differences were seen in HADS-Anxiety and HADS-Depressions scores. Women younger 
than 70 reported higher levels of Anxiety with improvement from baseline to year 1 and to year 2  in 
both groups. 
Pre-specified secondary QOL outcomes 
An interesting pattern in self-reporting of general pain was observed. The mean score at baseline 
was just over 20 in both groups, but without any improvement from baseline to year 1 or year 2 
independent of randomisation arm, which is at odds with some of the findings for the primary 
outcomes (global QOL, fatigue, chest-wall symptoms, body image and anxiety) where we observed 
an improvement from baseline. We investigated the potential impact of systemic treatments. 
Borderline effects were found for use of trastuzumab (P=0·06) and chemotherapy (P=0·08), possibly 
associated with the use of taxanes. No effect was found for endocrine therapy (none vs tamoxifen vs 
aromatase inhibitors).  
No between-group differences were observed for nausea/vomiting, sexual, role and social functions. 
Gradual improvement over time was observed without any effect of treatments. Role function and 
social function showing the biggest numerical improvement over time, in year 1 with continued 
improvement in year 2. Patients having radiotherapy reported larger improvements in their social 
function in comparison with those who did not. Patients reported very low scores on sexual 
functioning (mean of 11 out of 100).  We had good completion rate for the general sexual function 
questions 97% (914/947) but only 27% (253/914) patients completed the conditional sexual 
enjoyment questions at baseline suggesting that the vast majority of patients are not sexually active 
(Table2).  
The exploratory analysis of the other scales is in the web appendix page 5. All remaining scales and 
items did not show any impact of radiotherapy treatment and all show improvement or stability 
over time.  
Discussion 
To our knowledge, this is the first study investigating the impact of adjuvant radiotherapy on quality 
of life after mastectomy in a large randomised trial including a substantial, well characterised 
population of UK patients ǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂƚĞ-ƌŝƐŬ ?ďƌĞĂƐƚĐĂŶĐĞr. The key finding is that PMRT was 
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associated with worse local self-reported symptoms (pain, swelling, oversensitivity and skin 
ƉƌŽďůĞŵƐŝŶƚŚĞ “ĂƌĞĂŽĨƚŚĞĂĨĨĞĐƚĞĚďƌĞĂƐƚ ? ?ŝŶĐŽŵƉĂƌŝƐŽŶǁŝƚŚŶŽƌĂĚŝŽƚŚĞƌĂƉǇ ?ĂůƚŚŽƵŐŚƚŚĞƐĞ
symptoms improved over time. The estimated effect is small, with a difference ŝŶ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ?
between the radiotherapy and control group of 2·17 points; 95% CI 0·40, 3·94. There is published 
data on EORTC QLQ- ? ?ŽŶ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ?ǁŝƚŚŝŶŐƌŽƵƉƐŽƌ ?ƐĐŽƌĞƐĚŝĨĨĞƌĞŶĐĞ ?ďĞƚǁĞĞŶŐƌŽƵƉs that 
is clinically significant, but to the best of our knowledge, there is no such available data on EORTC-
BR23 scores 23. We opted to present the mean scores and standard deviations in order to allow 
comparisons with other studies. In an attempt to explore the clinical significance of the observed 
statistically significant difference, we looked at using a generic approach of 0.5 of the standard 
deviation to indicate minimally important difference.  Therefore, we calculated the standard 
ĚĞǀŝĂƚŝŽŶŽĨƚŚĞ ?ĐŚĂŶŐĞƐĐŽƌĞ ?for chest wall symptoms from baseline to year 1 in the control group. 
24  The standard deviation was 17.3 and a score 8.65 is likely to indicate a clinically meaningful 
difference. The observed difference of 2.17 is relatively small and unlikely to be of clinical 
significance, which is of course reassuring for patients and clinicians. Recent guidelines from Federal 
Drugs Administration (FDA) recommend establishing a meaningful change in patient reported 
outcomes measures at the individual level (i.e., defining a responder) versus at the treatment group 
level 25. The definition of a responder bĞŝŶŐ “ĂƐĐŽƌĞĐŚĂŶŐĞŝŶĂŵĞĂƐƵƌĞ ?ĞǆƉĞƌŝĞŶĐĞĚďǇĂŶ
individual patient over a predetermined time period that has been demonstrated in the target 
ƉŽƉƵůĂƚŝŽŶƚŽŚĂǀĞĂƐŝŐŶŝĨŝĐĂŶƚƚƌĞĂƚŵĞŶƚďĞŶĞĨŝƚ ?. Using this approach and a  ?ĐŚĂŶŐĞƐĐŽƌĞ ?ŽĨ ? ? ? ?
as a cut-ŽĨĨƐĐŽƌĞĨŽƌĐůŝŶŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞǁĞĂƉƉůŝĞĚ ?ƌĞƐƉŽŶĚĞƌĂŶĂůǇƐŝƐ ? (web appendix page 7).  We 
ĐĂůĐƵůĂƚĞĚƉƌŽƉŽƌƚŝŽŶƐŽĨƉĂƚŝĞŶƚƐǁŚŽƐĞƐĐŽƌĞƐ ?ŝŵƉƌŽǀĞĚ ?ďǇ< - 8.65 points between baseline and 
year 1 ?ƚŚŽƐĞǁŚŽƌĞŵĂŝŶĞĚ ?ƐƚĂďůĞ ? ?ŶŽĐŚĂŶŐĞ ? ?change score=+/-8.65) and those whose scores 
 ?ǁŽƌƐĞŶĞĚ ?ďǇхн ? ? ? ?ƉŽŝŶƚƐ ?dŚŝƐ ?ƌĞƐƉŽŶĚĞƌĂŶĂůǇƐĞƐ ? showed that 16.3% (63/386) of patients 
ƌĞĐĞŝǀŝŶŐƌĂĚŝŽƚŚĞƌĂƉǇƌĞƉŽƌƚĞĚĐůŝŶŝĐĂůůǇŵĞĂŶŝŶŐĨƵůǁŽƌƐĞ ?ĐŚĂŶŐĞƐĐŽƌĞ ?ǀƐ ? ? ? ?й(46/385) of 
those without radiotherapy. In other words, 4.4% more patients on radiotherapy experience worse 
chest wall symptoms than those not receiving PMRT. This way of interpretation of results may be 
more informative to clinicians and patients, but a note of caution is appropriate due to the 
assumptions described above.  
There was no impact of radiotherapy to the chest wall on arm symptoms (axillary radiotherapy was 
prohibited in the trial), body image, overall QOL, physical function, fatigue or symptoms of anxiety or 
depression. Exploratory analyses showed that systemic chemotherapy treatment had an additive 
borderline ĞĨĨĞĐƚŽŶƉĂƚŝĞŶƚƐ ?ĐŚĞƐƚǁĂůůĂŶĚĂƌŵƐƐǇŵƉƚŽŵƐďƵƚǁŝƚŚŽƵƚĂŶŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚƚŚĞ
radiotherapy treatment. This is consistent with other studies 26.   
Sentinel node biopsy procedure is the current standard surgical staging procedure for the axilla. In 
SUPREMO about a quarter of patients (those with pN0 (sn) tumours) in the main and QoL substudy 
underwent limited axillary surgery (sentinel node biopsy or nodal sampling). The extent of axillary 
surgery had no impact on any of the pre-specified QOL outcomes, including arm symptoms. This is 
perhaps an unexpected finding and could be due to lack of sensitivity of the EORTC BR23 scale 
(which has 3 items on  ?ƉĂŝŶŝŶĂƌŵŽƌƐŚŽƵůĚĞƌ ? ? ?ƐǁŽůůĞŶĂƌŵŽƌŚĂŶĚ ?ĂŶĚ ?ĚŝĨĨŝĐƵůƚǇƌĂŝƐŝŶŐǇŽƵƌ
Ăƌŵ ? ? ?The impact of radiotherapy to the axilla on arm symptoms cannot be evaluated in the 
SUPREMO trial, as this was prohibited. Our findings are not generalisable to women who were 
treated with both an axillary nodal dissection and regional nodal radiotherapy. This treatment is 
generally reserved for patients with higher nodal load (N2 and N3 disease) than included in the 
SUPREMO trial (pN0 or pN1).  
Neo-adjuvant treatment was allowed in a later protocol version (version 29), but the number of 
treated patients is too small (n=8) for valid conclusions and therefore we did not perform any 
between group comparisons.   
We observed a low rate of immediate breast reconstruction (only 111 patients). This procedure was 
associated with higher fatigue levels and slower recovery in comparison with no immediate 
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reconstruction but no impact on body image or the other QOL outcomes. The estimated effect of 
immediate reconstruction on fatigue was 5.32, corresponding to a small clinically meaningful 
difference23. This was an exploratory analysis and we used a generic QOL and body image 
questionnaires rather than breast-reconstruction instruments (such as BREAST-Q), which is likely less 
sensitive to specific outcomes 17. Due to the low rates of reconstruction in SUPREMO, we do not 
have the power to assess between group differences taking into account the dose schedules in the 
radiotherapy group.  A direct comparison of conventional versus hypo-fractionation for chest wall 
radiotherapy after breast reconstruction is being carried out in North America by the Alliance for 
Clinical Trials in Oncology (NCT03414970). The primary objective is to evaluate whether the 
reconstruction complication rate at 24 months post radiation is non-inferior with hypofractionation. 
The trial is ongoing and will complete recruitment in 2021, with final results in August 2025.  
It should be noted that the observed levels of reconstructive surgery (either immediate or delayed 
to year 2) are low in the range of 10-13%. This likely reflects the pattern of care in the period of the 
SUPREMO trial recruitment (2006-2013) or may be due to concerns of entering patients who had 
reconstruction into a trial of radiotherapy. There appears to be a trend in using more autologous 
procedures in patients who had radiotherapy and more implants/expanders in those not receiving 
radiotherapy. Due to the small number of reconstructions, SUPREMO trial cannot provide useful 
information on the impact of radiotherapy on breast reconstruction, and further evidence is needed. 
We are collecting further information on delayed (beyond 2 years) reconstructions, which will be 
analysed at 5 and 10 years and provide valuable information on rates of breast reconstruction across 
the UK, ĂƐǁĞůůĂƐŝƚƐŝŵƉĂĐƚŽŶƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐĂŶĚƐĂƚŝƐĨĂĐƚŝŽŶǁŝƚŚďŽĚǇŝŵĂŐĞ ? 
Most of the published literature relating to the impact of adjuvant radiotherapy on QOL relates to 
non-randomised studies, often of small size, which may be subject to selection bias and neither 
surgery, radiotherapy nor were systemic treatments subject to pre-specified quality assurance. 
Comparisons are often difficult because of differing types of surgery, stage of disease, QOL measures 
used and time-points of QOL assessment. Studies often included both patients treated by 
mastectomy and breast conserving surgery. The START trial looked at late effects of different 
schedules of radiotherapy at 5 years and found that up to a third of women reported moderate or 
marked pain in the arm and shoulder and more than 10% experienced arm/hand swelling12. The trial 
included a small number of mastectomy patients (about 20%) and although the QOL results are 
consistent with ours, they are not directly comparable since only 10% had chemotherapy and 20% 
had regional nodal irradiation in addition to breast/chest wall radiotherapy. The experience of 
breast/arm symptoms over 5 years represents chronic morbidity that has stronger association than 
cosmesis with long-term quality of life, making these important outcomes in clinical trials27. 
The Moving Beyond Cancer psychosocial intervention trial studied the QOL of 558 women with stage 
1 and 2 breast cancer treated with surgery alone (breast conserving or mastectomy), surgery with 
radiation, or surgery followed by chemotherapy and radiation  over 1 year, using SF-36 
questionnaire. Similar to our study, physical and psychosocial function improved significantly over 
time. However, the measures of QOL differ from our study and details of chemotherapy regimes  
and staging were not available in the absence of case record review26. A similar pattern of 
improvement in a range of symptoms and QOL measures in the first year post diagnosis was 
observed in a cohort study of 285 women with early breast cancer, treated with surgery (just >20% 
had mastectomy), adjuvant radiotherapy (74%) and systemic therapy in (just >30% of the patients)  
28.  
Finally, we observed that younger women reported worse body image (if under 45) and anxiety 
problems (if under 70 years). This finding is supported by other breast cancer QOL studies, is 
concordant with clinical experience and emphasises the need for targeted psychological 
interventions in those women11,29. Younger women also reported higher general pain scores which   
did not improve with time, and this was not related to the use of aromatase inhibitors (data not 
shown). The reasons for this are not clear. Persistent pain following breast surgery (breast 
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conserving or mastectomy) was reported by half of the patients in a population-based prospective 
study of over 3000 patients. The pain was commoner after adjuvant radiotherapy and in younger 
women. 30 The same finding was also reported in a randomised trial of radiotherapy after breast 
conserving therapy 13,30. The wide variation in reports (25% -60%) may relate to varying definitions of 
pain, different methods of pain assessment and mix of surgery and adjuvant therapy. There is 
insufficient evidence to draw conclusions on each of the treatment-related risk factors for pain. 
The scores on sexual functioning and sexual enjoyment indicated that the majority of the patients 
were not sexually active, without between group differences. These observations are consistent with 
other reports.  
Several strengths of SUPREMO QOL substudy should be mentioned. It is the largest post-
mastectomy study which is investigating a well-defined large population of patients treated by 
mastectomy, which was    representative of women with early  ?ŝŶƚĞƌŵĞĚŝĂƚĞ-ƌŝƐŬ ? breast cancer in 
the UK. Individuals in the QOL study were recruited from almost all UK sites. Only 10 out of 111 sites 
did not recruit any of their 66 patients, a relatively small number of centres and unlikely to have an 
impact. We do not know the reasons for the low consent rates in some centres, but it may be 
related to availability of local resources (dedicated clinical research nurses).  This was a large 
pragmatic study and resources were not available to monitor closely consent rates by centre or to 
provide extra support.  
The QOL study was multi-centre from across the UK, representing a wide geographical range, thus 
minimising participating centre bias. The pre-specified QOL sample size was achieved and exceeded, 
strengthening our confidence in the findings. The trial was sufficiently large to allow explorative 
evaluation of the effects of age and multi-modality treatments. High levels of adherence to 
questionnaire completion over time were attained (>70%). In addition, guidelines on surgery, 
radiotherapy and systemic therapy were standardised in the protocol, so any variations in these 
treatment modalities between treatment arms are unlikely to influence the results.  
The main limitation of the QOL substudy is not having a true pre-treatment baseline QOL 
assessment, as all patients were randomised following mastectomy. The relatively low QOL scores at 
the time of randomisation may be explained by the recent breast cancer diagnosis and the surgical 
procedure, and the subsequent improvement in almost all scores, is to be expected.  We did not 
record QOL scores during or shortly after the allocated radiotherapy treatment, so any differences in 
acute symptoms between the groups, which may predict later toxicity, have not been captured. In 
addition, since the main trial is ongoing and the loco-regional control and survival status of the 
patients in the QoL substudy are not known to us, it is possible patients who had relapsed or died 
may have had different patterns of QOL.  
A larger proportion of participants in the QOL study received the dose fractionation schedule as 40 
Gy in 15 fractions (69%) compared to 52% in the main trial, where a larger proportion of 27% 
received 50 Gy in 25 fractions. This difference reflects the variations between the standard practice 
in UK and EORTC centres at the time of the trial.  
At this 2-year analysis we have not evaluated any effect of fractionation on the QOL outcomes. 
However, as the clinical significance of the increased chest wall symptoms in the radiotherapy group 
at 2 years may be relatively limited, we do not expect a major clinical impact of fractionation at this 
early time point. We expect that the difference in symptoms reported by patients between no 
radiotherapy and 40-50 Gy will be larger than any difference observed between fractionation 
schedules. The influence of radiation dose fractionation and technique and the radiation dose 
parameters to organs at risk will be the subject of a more detailed analysis to be performed in the 
irradiated group, including evaluation of toxicity (physician scoring). The results will be reported in a 
separate publication, focusing on the specific technical aspects of the radiotherapy. 
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This paper presents a pre-planned analysis at 2 years post randomisation, with the main QOL 
analysis being planned at 5 years and QOL data to be collected for 10 years to capture late adverse 
events. Clearly our results are preliminary and we are therefore cautious in our interpretation. 
However, it is a reassuring that the loco-regional symptoms are minimal and do not impair global 
QOL and diminish over the initial 2 years of follow up.   While it might be argued that analysing QOL 
at 2 years is too premature, this was a pre-planned analysis. We considered it appropriate to identify 
any potential early signals of a significant impact on QOL in the absence of a definite oncological 
outcome. If severe QoL effects were to be identified early, then this would be relevant for clinical 
decision making in the absence of information on long-term survival benefit. The recent North 
American guidelines on post mastectomy radiotherapy 7 emphasise the importance of shared 
decision making between physician and patient in weighing up the benefits and toxicity of treatment 
in patients with 1- 3 positive node undergoing axillary node clearance. Information on the impact of 
PMRT on QOL may help inform this decision-making process, even before the main trial outcomes 
become available.   Further analyses will be reported at 5 and 10 years to determine if the trends at 
2 years are sustained. It is possible that late radiotherapy toxicity not seen within the first two years 
(such as progressive chest wall fibrosis or increased cardiac toxicity due to the combination of 
radiotherapy and anthracycline-based chemotherapy) may be detected on longer term follow-up 
and should be captured in our 5 and 10 year analyses. However, we recognise that late cardiac 
toxicity from radiotherapy may occur beyond 10 years. 
 
The impact on PMRT on 10-year survival, the primary end-point of the main SUPREMO trial, will not 
be known before 2023. In the meantime, the decision to administer or omit PMRT can be considered 
 ?ƉƌĞĨĞƌĞŶĐĞsensitivĞ ? for patients in the SUPREMO trial risk category of 1-3 positive lymph nodes, as 
both options are legitimate. The patients will be in a better position to make a value judgment on 
what they consider relevant for them, given the data on various QOL domains presented in this 
report. Both physicians and patients may thus be helped when weighing up the individual estimates 
of possible benefits of radiotherapy against the impact of PMRT on toxicity and QOL endpoints.  
In conclusion, chest wall radiotherapy led to more chest wall symptoms up to 2 years post-
randomisation, but the difference is small and unlikely to be clinically significant. There was no 
impact on the other pre-specified QOL domains.  However, the trend for worse QOL scores for 
anxiety, body image and chest-wall symptoms in younger women irrespective of irradiation warrants 
further investigation. Longer term follow-up at 5 and 10 years will be needed to see if these early 
trends in quality of life are sustained. 
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Tables 
dĂďůĞ ? ?WĂƚŝĞŶƚƐ ?ĚĞŵŽŐƌĂƉŚŝĐĂŶĚĐůŝŶŝĐĂůĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ 
Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Demographic 476 471 835 853 
Age (mean and SD) 56·3 (11·3) 55·8 (10·8) 55·9 (11·2) 55·8 (11·3) 
Menopausal status (number, %) 
Pre-menopausal 
Peri-menopausal 
Post-menopausal 
Not known 
 
126 (26·5) 
43 (9·0) 
290 (60·9) 
17 (3·6) 
 
135 (28·7) 
52 (11·0) 
268 (56·9) 
16 (3·4) 
 
246 (29·5) 
68 (8·1) 
483 (57·8) 
38 (4·6) 
 
243 (28·5) 
85 (10·0) 
475 (55·7) 
50 (5·9) 
     
Tumour characteristics     
Side of primary tumour (number, %) 
Left 
Right 
 
238 (51·2) 
227 (48·8) 
 
216 (47·8) 
236 (52·2) 
 
398 (50·1) 
396 (49·9) 
 
407 (51·3) 
387 (48·7) 
Tumour size (number, %) 
ч ?Đŵ 
2·1-5 cm 
>5 cm 
Unknown 
 
132 (27·7) 
337 (70·8) 
5 (1·1) 
2 (0·4) 
 
138 (29·3) 
332 (70·5) 
1 (0·2) 
0 
 
249 (29·8) 
566 (67·8) 
4 (0·5) 
16 (1·9) 
 
261 (30·6) 
566 (66·4) 
4 (0·5) 
22 (2·6) 
Tumour grade (number, %) 
I 
II 
III 
Not specified 
 
20 (4·2) 
190 (39·9) 
262 (55·0) 
4 (0·8) 
 
23 (4·9) 
195 (41·4) 
250 (53·1) 
3 (0·6) 
 
46 (5·5) 
335 (40·1) 
432 (51·7) 
22 (2·6) 
 
57 (6·7) 
333 (39·0) 
432 (50·6) 
31 (3·6) 
Histological type (number, %) 
Ductal 
Lobular 
Mucinous 
Tubular 
Adenocarcinoma 
Other  
 
372 (78·5) 
58 (12·2) 
5 (1·1) 
1 (0·2) 
3 (0·6) 
35 (7·4) 
 
374 (79·4) 
49 (10·4) 
1 (0·2) 
3 (0·6) 
5 (1·1) 
39 (8·3) 
 
641 (78·2) 
95 (11·6) 
7 (0·9) 
4 (0·5) 
16 (2·0) 
57 (7·0) 
 
661 (79·5) 
89 (10·7) 
1 (0·1) 
4 (0·5) 
13 (1·6) 
63 (7·6) 
Molecular markers  W (number, %) 
ER+/PR+ 
ER+/PR- 
ER-/PR+ 
ER-/PR- 
ER+/PR unknown 
ER-/PR unknown 
 
Her2 positive 
Her2 negative 
Not measured 
 
218 (46·8) 
48 (10·3) 
5 (1·1) 
87 (18·7) 
96 (20·6) 
12 (2·6) 
 
140 (29·7) 
286 (60·7) 
45 (9·6) 
 
 
217 (46·7) 
48 (10·3) 
0 (0) 
93 (20·0) 
100 (21·5) 
7 (1·5) 
 
145(31·1) 
281 (60·2) 
41 (8·8) 
 
 
417 (51·5) 
83 (10·3) 
8 (1·0) 
156 (19·3) 
131 (16·2) 
15 (1·9) 
 
273 (33·5) 
475 (58·2) 
68 (8·3) 
 
 
416 (50·6) 
99 (12·0) 
3 (0·4) 
162 (19·7) 
132 (16·0) 
11 (1·3) 
 
269 (32·5) 
469 (59·9) 
63 (7·6) 
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Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Axillary Nodes (number, %) 
0 (negative) 
1- 
2- 
3- 
Not known 
 
130 (27·3) 
180 (37·8) 
101 (21·2) 
63(13·4) 
2 (0·4) 
 
113 (24·0) 
199 (42·3) 
111 (23·6) 
48 (10·2) 
0 
 
219 (26·2) 
316 (37·8) 
178 (21·3) 
107 (12·8) 
15 (1·8) 
 
212 (24·9) 
338 (39·6) 
194 (22·7) 
88 (10·3) 
21 (2·5) 
     
Treatment     
Breast Surgery (number, %) 
Mastectomy only 
Immediate breast reconstruction 
prior to RT 
Late breast reconstruction  
 
371 (77·9) 
50 (10·5) 
 
55 (11·6) 
 
359 (76·2) 
61 (13·0) 
 
51 (10·8) 
 
653 (78·2) 
85 (10·2) 
 
97 (11·6) 
 
669 (78·4) 
97 (11·4) 
 
87 (10·2) 
     
Axillary surgery (number, %) 
SLN / node sampling 
SLN plus ANC (Axillary node 
clearance) 
ANC (without SLN) 
 
131 (27·9) 
138 (29·4) 
 
201 (42·8) 
 
108 (22·9) 
124 (26·3) 
 
239 (50·7) 
 
207 (25·5) 
229 (28·2) 
 
377 (46·4) 
 
189 (22·8) 
224 (27·0) 
 
417 (50·2) 
Systemic treatment (number Yes, %) 
Neo-adjuvant chemotherapy1  
Adjuvant chemotherapy 
Anthracyclines 
Taxanes 
Trastuzumab 
 
Endocrine therapy (number Yes, %) 
Neo-adjuvant 
Adjuvant 
Aromatase inhibitor 
Tamoxifen 
Other  
 
1/173 (0·58) 
395/476(83·0) 
372/395(94·2) 
197/395(49·9) 
91/454 (20·5) 
 
 
2/200 (1·0) 
349 (73·3) 
173/349(49·6) 
174/349(49·9) 
2/349 (0·6) 
 
7/173 (4·1) 
401/471(85·1) 
379/401(94·5) 
207/401(51·6) 
92/460 (20·0) 
 
 
8/206 (3·9) 
363 (77·1) 
195/363(53·7) 
168/363(46·3) 
0/363 (0) 
 
7/243 (2·9) 
682/835(81·7) 
636/682(93·3) 
392/682(57·5) 
150/782(19·2) 
 
 
10/288 (3·5) 
598 (71·6) 
275/598(46·0) 
319/598(53·3) 
4/598 (0·8) 
 
16/269 (6·0) 
709/853(83·1) 
655/709(92·4) 
418/709(59·0) 
166/806(20·6) 
 
 
17/316 (5·4) 
631 (73·9) 
314/631(49·8) 
314/631(49·8) 
3/631 (0·5) 
1 Only recorded in protocol v29 onwards; the denominator is the total number of recorded 
chemotherapy treatments from protocol v29 onwards 
ER- estrogen receptor; PR  W progesteron receptor; SLN- sentinel lymph node(s) procedure; ANC  W 
axillary node clearance 
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Table 2. Quality of Life (QOL) scores (Standard Deviations, SD) at baseline, year 1 and year 2 follow-
up 
 
QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Age at 
randomisation 
56·3 (11·3) 55·8 (10·8) 56·5 (10·9) 56·1 (10·4) 56·8 (10·9) 56·1 (10·4) 
       
Primary endpoints      
EORTC QLQ-C30       
Global 
Health/QOL* 
60·9 (21·6) 60·4 (20·8) 70·0 (20·5) 70·0 (19·8) 70·2 (20·5) 71·8 (20·1) 
Fatigue** 41·6 (25·2) 43·0 (26·1) 30·3 (23·2) 31·0 (24·1) 29·2 (24·2) 27·5 (23·8) 
Physical 
Functioning* 
79·6 (20·2) 80·1 (19·6) 81·9 (19·0) 81·1 (19·1) 82·0 (18·6) 82·1 (19·3) 
       
EORTC QLQ-BR23       
Arm symptoms** 20·3 (20·5) 21·2 (21·7) 21·2 (21·7) 22·4 (22·0) 20·7 (21·4) 19·9 (20·3) 
Chest wall/breast 
symptoms** 
17·3 (17·0) 18·1 (18·3) 13·1 (16·3) 16·1 (16·7) 11·6 (14·6) 14·1 (15·8) 
       
Body Image 
Scale** 
10·3 (7·9) 11·1 (8·2) 9·3 (7·6) 9·8 (7·7) 8·1 (6·7) 8·7 (7·4) 
       
Hospital Anxiety and 
Depression Scale (HADS) 
     
Anxiety 6·2 (4·4) 6·1 (4·3) 6·8 (4·7) 6·5 (4·4) 6·3 (4·3) 6·5 (4·4) 
Depression 4·5 (3·7) 4·6 (3·7) 4·2 (3·7) 4·2 (3·8) 4·0 (3·5) 4·2 (3·9) 
       
Secondary endpoints      
EORTC QLQ-C30       
Role Functioning * 65·2 (30·9) 63·0 (30·5) 79·3 (27·1) 78·8 (25·8) 79·7 (27·6) 81·0 (26·9) 
Social Functioning 
* 
65·5 (28·7) 64·0 (29·1) 79·4 (25·6) 80·3 (24·7) 80·5 (26·1) 83·9 (25·2) 
Pain** 22·6 (26·5) 24·8 (27·9) 21·7 (26·8) 23·7 (26·5) 23·4 (27·3) 21·6 (25·9) 
Nausea 
Vomiting** 
11·2 (17·6) 11·5 (20·1) 5·3 (13·1) 5·1 (12·1) 4·6 (12·2) 5·1 (13·6) 
       
EORTC QLQ-BR23       
Sexual 
Functioning* 
11·5 (18·1) 
n=455 
12·5 (19·0) 
n=459 
15·7 (20·5) 
n=372 
17·6 (21·2) 
n=374 
16·3 (21·7) 
n=325 
18·1 (22·3) 
n=353 
       
Exploratory variables      
EORTC QLQ-C30       
Emotional 
Functioning* 
74·7 (22·6) 73·7 (24·4) 75·2 (23·6) 75·2 (22·3) 77·3 (22·5) 75·7 (23·3) 
Cognitive 
Functioning* 
77·1 (23·4) 75·0 (26·1) 78·2 (22·8) 78·2 (22·9) 78·6 (22·8) 78·2 (23·8) 
Dyspnoea** 20·8 (26·4) 20·0 (26·1) 14·6 (23·5) 14·8 (23·0) 14·3 (23·2) 13·4 (22·5) 
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QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Insomnia** 36·3 (31·1) 37·2 (32·8) 36·4 (33·5) 38·5 (32·8) 33·9 (31·9) 35·0 (30·5) 
Appetite loss** 20·7 (28·9) 19·2 (27·9) 9·5 (19·8) 8·7 (18·5) 9·1 (19·9) 9·0 (20·7) 
Constipation** 18·2 (26·3) 17·0 (26·1) 14·9 (24·5) 14·5 (24·1) 17·6 (27·7) 14·5 (24·3) 
Diarrhoea** 11·9 (20·7) 12·1 (23·8) 7·6 (17·5) 8·4 (18·7) 5·4 (15·1) 8·7 (19·1) 
Financial 
difficulties** 
23·9 (33·1) 23·2 (31·7) 15·8 (28·5) 17·1 (27·8) 14·1 (27·0) 13·8 (26·6) 
       
EORTC QLQ-BR23       
Sexual 
enjoyment* 
49·9 (26·9) 
n=121 
53·0 (29·1) 
n=132 
54·4 (28·3) 
n=136 
56·5 (26·5) 
n=144 
52·5 (26·1) 
n=115 
56·6 (28·8) 
n=136 
Future 
perspective** 
45·8 (31·2) 46·4 (32·8) 49·8 (32·3) 50·9 (31·6) 54·4 (30·1) 54·1 (30·9) 
Systemic therapy 
side-effects** 
34·8 (23·1) 35·2 (22·7) 19·3 (15·2) 19·6 (15·6) 18·6 (14·9) 18·3 (15·0) 
Hair loss** 29·6 (37·5) 31·7 (39·3) 6·2 (20·4) 6·4 (21·8) 3·8 (20·7) 4·9 (17·1) 
       
EQ-5D-3L*** 0·74 (0·22) 0·74 (0·22) 0·75 (0·25) 0·75 (0·24) 0·76 (0·24) 0·77 (0·22) 
 
 
*EORTC QLQ-C30 Functional scores- range 0-100 (higher score = good functioning) 
** EORTC QLQ-C30 Symptom scores  W range 0-100 (higher score = worse symptoms) 
*** EQ-5D-3L score-range 0-1. 
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Table 3. Mixed effects models (fixed effects) for the primary QOL outcomes 
 
Outcome Model variable Estimate of 
effects 
95% CI p 
Global 
QOL (C30) 
Baseline score 
Age- ref* >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·57 
- 
1·12 
3·25 
3·54 
0·75 
1·39 
-0·63, -0·52 
- 
-3·45, 5·78 
-0·62, 7·12 
-0·28, 7·36 
-0·46, 1·97 
-0·92, 3·71 
<0·0001 
- 
0·64 
0·10 
0·069 
0·23 
0·24 
 Adjusted mean 
ŽĨ ?ĐŚĂŶŐĞ
ƐĐŽƌĞƐ ?**  
95% CI p-value*** 
   
RT 
No RT 
8·63 
7·23 
6·86, 10·40 
5·46, 9·01 
<0·0001 
<0·0001 
Fatigue 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Immediate 
reconstruction 
Ref no recon 
RT  Wref no RT 
-0·59 
- 
-2·41 
-4·14 
-3·13 
-1·83 
5·32 
 
 
-1·93 
-0·65, -0·54 
- 
-8·07, 3·26 
-8·84, 0·56 
-7·73, 1·47 
-3·20, -0·46 
0·94, 9·69 
 
 
-4·70, 0·84 
<0·0001 
- 
0·40 
0·079 
0·18 
0·0094 
0·017 
 
0·17 
RT 
No RT 
-9·54 
-7·61 
-12·19, -6·89 
-10·35, -4·87 
<0·0001 
<0·0001 
Physical 
function 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·41 
- 
7·91 
7·06 
4·29 
0·20 
-0·17 
-0·46, -0·35 
- 
3·94, 11·87 
3·80, 10·32 
1·06, 7·51 
-0·68, 1·08 
-2·13, 1·79 
<0·0001 
- 
<0·0001 
<0·0001 
0·0092 
0·65 
0·87 
RT 
No RT 
-0·02 
0·14 
-1·53, 1·48 
-1·36, 1·65 
0·97 
0·85 
Chest wall 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT  Wref no RT 
-0·57 
- 
4·49 
1·88 
2·36 
-1·34 
3·74 
2·17 
-0·62, -0·52 
- 
0·59, 8·39 
-1·46, 5·22 
-0·79, 5·51 
-2·36, -0·31 
0·87, 6·61 
0·40, 3·94 
<0·0001 
- 
0·022 
0·26 
0·14 
0·010 
0·011 
0·016 
RT 
No RT 
-3·13 
-5·30 
-4·74, -1·51 
-6·88, -3·71 
0·0002 
<0·0001 
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Arm and 
shoulder 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT  Wref no RT 
-0·51 
- 
0·86 
2·89 
2·76 
-0·93 
6·15 
-0·53 
-0·57, 0·45 
- 
-4·42, 6·14 
-1·64, 7·41 
-1·51, 7·03 
-2·22, 0·37 
2·26, 10·05 
-2·92, 1·86 
<0·0001 
- 
0·74 
0·21 
0·20 
0·16 
0·0021 
0·66 
RT 
No RT 
-1·44 
-0·91 
-3·63, 0·75 
-3·06, 1·24 
0·19 
0·40 
Body 
Image 
Scale  
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·39 
- 
1·96 
1·39 
0·83 
-0·91 
-0·09 
-0·43, 0·34 
- 
0·53, 3·39 
0·20, 2·58 
-0·33, 1·99 
-1·28, -0·55 
-0·79, 0·61 
<0·0001 
- 
0·0074 
0·022 
0·15 
<0·0001 
0·79 
RT 
No RT 
-1·36 
-1·27 
-1·90, -0·83 
-1·81, -0·73 
<0·0001 
<0·0001 
HADS-
Anxiety 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·30 
- 
1·69 
1·36 
1·21 
-0·05 
-0·16 
-0·35, -0·25 
- 
0·86, 2·53 
0·67, 2·06 
0·53, 1·90 
-0·29, 0·18 
-0·57, 0·25 
<0·0001 
- 
<0·0001 
<0·0001 
0·00050 
0·66 
0·44 
RT 
No RT 
0·44 
0·60 
0·13, 0·76 
0·29, 0·92 
0·0061 
0·00022 
HADS- 
Depression 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·35 
- 
0·07 
-0·05 
-0·04 
0·02 
-0·14 
-0·41, 0·30 
- 
-0·73, 0·87 
-0·72, 0·61 
-0·69, 0·62 
-0·16, 0·20 
0·54, 0·25 
<0·0001 
- 
0·87 
0·88 
0·91 
0·94 
0·48 
RT 
No RT 
-0·19 
0·05 
-0·50, 0·11 
-0·35, 0·25 
0·21 
0·75 
Pain (C30) Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·51 
- 
-0·18 
2·76 
2·18 
0·31 
-0·65 
-0·57, -0·46 
- 
-6·16, 5·80 
-2·17, 7·69 
-2·70, 7·06 
-1·29, 1·91 
-3·62, 2·33 
<0·0001 
- 
0·95 
0·27 
0·38 
0·70 
0·67 
RT 
No RT 
0·28 
0·93 
-1·99, 2·56 
-1·35, 3·20 
0·81 
0·42 
* ref =reference category in the mixed-effects models 
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** the adjusted mean for the individual arms is the mean ŽĨƚŚĞ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ? ? ?ĚĞĨŝŶĞĚĂƐchange 
from baseline to year 1 and from baseline to year 2) in each of the treatment groups, adjusted for 
baseline score, visit, and age;  
***p values  - whether each of the means ŽĨƚŚĞ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ? within each individual arm is 
significantly different from zero (i.e., improvement or deterioration in scores from baseline) 
 
